ImClone explores its options

ImClone Systems, the $3bn (€2.4bn) US biopharmaceutical company, has hired Lazard for the first time to conduct a strategic review that could include a merger or sale.

The Lazard managing directors working on the deal are Kenneth Jacobs, Jason Bernhard and Stephen Sands.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump